Aivita Health Group invests in four interconnected technology platforms that link laboratories, clinics, and everyday life. Together they form the backbone of our vertically integrated health ecosystem.
Each platform is designed to be modular and scalable – so that innovations developed with our partners can be deployed across MENA, Asia, and future global hubs in a consistent, quality-assured way.
Our iPSC Regenerative Platform is built on induced pluripotent stem cell technology – reprogramming adult cells into a pluripotent state so they can be differentiated into multiple tissue types.
This foundation enables disease modelling, drug screening, and the future development of personalised regenerative protocols. In the medium term, iPSC-derived cell lines and exosomes will support Aivita's Dubai clinics and regional partners through standardised, traceable biological products.
Our AI-powered medical diagnostics platform creates a secure, intelligent personal health database, helping physicians integrate lab reports, imaging, prescriptions, and visit notes into one longitudinal view – with AI-generated summaries and decision support.
Our Stem Cell & Exosome Applications platform focuses on safe, biologically active products that can be translated into real-world regenerative protocols. Axel Biotechnology's patent-pending exosome QC system reveals true exosome quality through standardised, quantifiable biological and physical indicators.
Vita-X is Aivita's therapeutic movement platform where medical science meets artistic expression. Rooted in sports medicine, physical therapy, and dance movement therapy, Vita-X programmes are designed to support spine alignment, joint mobility, balance, and emotional regulation.
In the long term, Vita-X will be integrated with Aivita's AI and clinic platforms – allowing data from movement sessions, wearables, and assessments to inform personalised preventive and regenerative plans for active ageing, special needs, and recovery populations.
Establishing one of the first international-standard cell banks in the Middle East, providing the infrastructure for regional regenerative medicine development, iPSC-based solutions, and cross-border collaborations between Dubai, Asia, and future global hubs.
Aivita Health Group works with specialist partners who provide unique scientific capabilities and regulatory experience. These alliances give Aivita a defensible edge in exosome quality, iPSC platforms, and cross-border technology transfer.
These partnerships are structured to support both regulatory compliance and long-term commercial scalability – from early-stage pilots to multi-site deployment.
Aivita's Regional Expansion Blueprint connects MENA, Asia, and our future Global R&D Centre into one coordinated network – so that discoveries made in the lab can be rapidly translated into clinical programmes and health solutions across markets.
The goal is simple: use a coordinated R&D and deployment network to shorten the distance between scientific discovery and real-world health impact – starting from Dubai and extending across MENA, Asia, and future global hubs.